molnupiravir

Indications

Indicated for the treatment of mild to moderate coronavirus disease (COVID19) in adults over 18 years of age who have directly tested positive for the SARS-CoV-2 virus and are at high risk of developing severe COVID-19, including hospitalization or death.

Usage and Dosage

1. 800mg (4 200mg capsules), taken orally every 12 hours for 5 consecutive days, with or without food.

2. Take monabiravir as soon as possible after COVID-19 is diagnosed, and within 5 days after symptoms appear.

3. Swallow the whole capsule with water. Do not open or crush the capsule.

4. Since the safety and effectiveness have not yet been determined, monabiravir is not authorized for continuous use for more than 5 days.

5. If the patient misses a dose of monabiravir within 10 hours of the usual dose, the patient should take it as soon as possible and resume the normal dosing schedule. If a patient misses a dose by more than 10 hours, the missed dose should not be taken but the next dose should be taken at a regularly scheduled time. Patients should not double their dose to make up for a missed dose.

Precautions

Monabiravir is not recommended for use during pregnancy.

Reactions including anaphylaxis have been reported with monabiravir. If signs and symptoms of clinically significant hypersensitivity or anaphylaxis occur, discontinue monabiravir immediately.

Monabiravir is not approved for use in patients under 18 years of age because it may affect bone and cartilage growth.

Monabiravir is not recommended during pregnancy. Advise individuals of childbearing potential to use effective contraception correctly and continuously during treatment and for 4 days after the last dose of monabiravir.

Breastfeeding is not recommended during treatment and within 4 days after the last dose of monabiravir. Nursing patients may consider discontinuing breastfeeding and may consider pumping and discarding breast milk during treatment and for 4 days after the last dose of monabiravir.